http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kamruzzaman Selim, K.M.,Park, Mi Jin,Kim, Hong Mi,Kang, Inn Kyu Trans Tech Publications, Ltd. 2007 Key Engineering Materials Vol.342-343 No.-
<P>In the present study, superparamagnetic maltotrionic acid-coated magnetite nanoparticles (MAM) were surface modified with doxorubicin (DOX) and RGD peptide to improve their intracellular uptake, ability to target tumor cells and antitumer effect. RGD was added to the distal end of MAM aiming to construct an enhanced tumor targeting delivery system. To test its targeting effect, DOX, a widely used anticancer drug, was immobilized on the RGD-modified magnetite nanoparticles. DOX-coated magnetite nanoparticles were also prepared as a control. KB cell culture experiment showed that both DOX-modified nanoparticles and DOX-RGD peptide-modified magnetite nanoparticles (DRMAM) were internalized into the cells. But the uptake amount of DRMAMs was higher than that of DOX-modified nanoparticles. This result indicates that DRMAMs have a great potential to be used as contrast agent and antitumor medicine.</P>
Kamruzzaman Selim, K M,Xing, Zhi-Cai,Guo, Haiqing,Kang, Inn-Kyu Chapman and Hall ; Kluwer Academic Publishers 2009 Journal of materials science, Materials in medicin Vol.20 No.9
<P>In the current study, beta-galactose-carrying lactobionic acid (LA) was conjugated on the surface of mercaptoacetic acid-coated cadmium sulfide nanoparticles (CSNPs) to ensure specific recognition of liver cells (hepatocytes) and to enhance biocompatibility. Maltotrionic acid-coated CSNPs (MCSNPs) were also prepared for use as a control. The results showed that LA-immobilized CSNPs (LCSNPs) were selectively and rapidly internalized into hepatocytes and emitted more intense fluorescence images as well as demonstrated increased biocompatible behavior in vitro than those of CSNPs and MCSNPs. Furthermore, the uptake amount of LCSNPs into hepatocytes was higher than that of CSNPs and MCSNPs. All these results indicate that LCSNPs may find ever-growing applications in biological labels and detection or contrast agents in life science and medical diagnostics.</P>
Albumin-conjugated Cadmium Sulfide Nanoparticles and their Interaction with KB Cells
Selim, K.M. Kamruzzaman,Kang, Inn-Kyu,Guo, Haiqing The Polymer Society of Korea 2009 Macromolecular Research Vol.17 No.6
Cytotoxicity is a severe problem of cadmium sulfide nanoparticles(CSNPs) for use in biological systems. In the present study, mercaptoacetic acid-coated CSNPs were conjugated with bovine serum albumin (BSA) to improve biocompatibility. The surface properties of the CSNPs and albumin-conjugated CSNPs (ACSNPs) were characterized by XRD, UV, FTIR, EA, TEM and DLS. Human breast cancer cells (KB cells) were then cultured in the presence of the nanoparticles to evaluate the cytotoxicity of CSNPs and ACSNPs. Finally, the fluorescence intensity of the nanoparticles' aqueous solution was examined using a fluorescence spectrometer. The results showed that the cell compatibility and fluorescence intensity of ACSNPs were higher than those of CSNPs. The strongly luminescent features of the biocompatible ACSNPs are promising for use in biological fields such as cellular labeling, intracellular tracking and molecular imaging.
Surface Modification of Magnetites Using Maltotrionic Acid and Folic Acid for Molecular Imaging
Selim, K.M.Kamruzzaman,Lee, Joo-Hee,Kim, Sun-Jung,Xing, Zhicai,Kang, Inn-Kyu,Chang, Yong-Min,Guo, Haiqing The Polymer Society of Korea 2006 Macromolecular Research Vol.14 No.6
Highly hydrophilic, uniform, superparamagnetic and nontoxic maltotrionic acid (MA)-coated magnetite nano-particles (MAM) were prepared and characterized by TEM, DLS, XRD and VSM. MA was used to improve the biocompatibility, monodispersity and non-specific intracellular uptake of nanoparticles. Folic acid (FA) was subsequently conjugated to the MAM to preferentially target KB cells (cancer cells) that have folate receptors expressed on their surfaces and to facilitate nanoparticles in their transit across the cell membrane. Finally, fluorescence isothiocyanate (FITC) was added to the nanoparticles to visualize the nanoparticle internalization into KB cells. After the cells were cultured in a media containing the MAM and MAM-folate conjugate (FAMAM), the results of fluorescence and confocal microscopy showed that both types of nanoparticles were internalized into the cells. Nevertheless, the amount of FAMAM uptake was higher than that of MAM. This result indicated that nanoparticles modified with MA and FA could be used to facilitate the nanoparticle uptake to specific KB cells (cancer cells) for molecular imaging.
Lee, H.S.,Kim, S.D.,Lee, W.M.,Endale, M.,Kamruzzaman, S.M.,Oh, W.J.,Cho, J.Y.,Kim, S.K.,Cho, H.J.,Park, H.J.,Rhee, M.H. North-Holland ; Elsevier Science Ltd 2010 european journal of pharmacology Vol.627 No.1
Platelets, though anucleated, possess several transcription factors, including NF-κB, that exert non-genomic functions regulating platelet activation. Since platelets have not only been recognized as central players of homeostasis, but also participated in pathological conditions such as thrombosis, atherosclerosis, and inflammation, we examined rat platelet NF-κB expression and evaluated the effects of anti-inflammatory drug BAY 11-7082, an inhibitor of NF-κB activation, in platelet physiology. Western blotting revealed that rat platelets express NF-κB. BAY 11-7082, dose dependently, inhibited collagen- or thrombin-induced-platelet aggregation. ATP release, TXB<SUB>2</SUB> formation, P-selectin expression, and intercellular Ca<SUP>2+</SUP> concentration activated by collagen were reduced in BAY 11-7082-treated platelets. BAY 11-7082 elevated intracellular levels of cAMP, but not cGMP, and its co-incubation with cAMP-activating agent (forskolin) or its hydrolyzing enzyme inhibitor (3-isobutyl-1-methylxanthine, IBMX), synergistically inhibited collagen-induced-platelet aggregation. In addition, vasodilator-stimulated-phosphoprotein (VASP) phosphorylation was enhanced in BAY 11-7082-treated platelets, which was partially inhibited by a protein kinase A (PKA) inhibitor, H-89. Moreover, while p38 mitogen-activated protein kinase (MAPK) was not affected, BAY 11-7082 attenuated c-Jun N-terminal kinase 1 (JNK1) and extracellular-signal-regulated protein kinase 2 (ERK2) phosphorylations. In conclusion, BAY 11-7082 inhibits platelet activation, granule secretion, and aggregation, and that this effect is mediated by inhibition of JNK1 and ERK2 phosphorylations, and partially by stimulation of cAMP-dependent PKA VASP phosphorylation. The ability of BAY 11-7082 to inhibit platelet function might be relevant in cases involving aberrant platelet activation where the drug is considered as anti-atherothrombosis, and anti-inflammatory therapy.